• The presenter serves as primary contact for all correspondence regarding the abstract ( except if there is a Submitter ).
• The submission of an abstract constitutes a formal commitment by the person to be in Lugano and present the abstract (if accepted) orally or as a poster. It will not be possible to contribute to the program remotely.
• The presenter may nominate a co-author to present an abstract in his/her place provided that the name of the replacement is submitted by email to abstract@icml.ch within 48 hours of the outcome notification.
• The presenter of a clinical abstract cannot be an employee of a pharmaceutical and/or diagnostic company. Conversely, employees of such companies may submit and present non-clinical abstracts.

Upon submission of an abstract, the presenter is responsible for the following:   

• ensuring that all authors have read the abstract, agreed to be co-authors and accepted the 17-ICML submission policies and regulations;
• forwarding all correspondence regarding the abstract to all co-authors;
• releasing of the permission to live streaming, recording for multimedia coverage and including his/her presentation in the 17-ICML on-demand resources;
• disclosing any conflict of interest related to the data presented in the abstract, declaring the name of the company (s)he or any of the co-authors maintain a "relevant financial relationship" with.
  “Relevant financial relationships” are intended those relationships from which the authors or any individual with whom (s)he directly shares his/her income has received or may receive financial benefit within the past 24 months.
  The relationships that must be declared are: employment or leadership position in a company – consultant or advisory role - stock ownership – honoraria – research funding – travel grants – other remuneration. Unless otherwise indicated, it is implied that there are no conflicts of interests pertinent to the abstract.
• certifying that the same abstract has neither been nor will be previously published before the 17-ICML, except for Encore abstracts (abstracts presented at regional or national meetings with < 1’000 attendees, EBMT, AACR, ASCO and EHA 2023).
  Encore abstracts will include the sentence “EA - previously submitted to EBMT / AACR / ASCO / EHA 2023”.
  Furthermore, the presenter declares that the abstract will not be included as such in the scientific material produced in connection with any Satellite symposium held during the 17-ICML (the company organizing the Satellite symposium undertakes to verify that the abstract included in the material is formally different from the one submitted to  the 17-ICML).
• declaring how the research was funded (by a pharmaceutical, biotech or other commercial company or by a Foundation or academic group) and naming the organization(s) funding the study.

Encore abstracts (EA) were accepted only if already submitted to and/or presented at:

• regional or national meetings (up to < 1’000 attendees);
• EBMT, AACR, ASCO and EHA, the large international meetings which are organized in the same period as the 17-ICML (March – July) by the European Society for Blood and Marrow Transplantation (EBMT), American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA).

Encore abstracts (EA) include the sentence “EA - previously submitted to EBMT / AACR / ASCO / EHA 2023”.

A limited number of travel grants, sponsored by the Swiss Cancer League and by the ICML Organizing Committee, are provided to young investigators (less than 35 years old), whose abstract has been accepted for an oral or poster presentation.

The selection was made on the basis of the abstract evaluation results.

Congratulations to the following young investigators:

Jan-Paul Bohn, Innsbruck, AT
Berit Brinkmann, Heidelberg, DE
Paul Jan Bröckelmann, Cologne, DE
Dana Casey, Chapel Hill, NC, US
Anja Fischer, Ulm, DE
Ayumi Fujimoto, Tokyo, JP
Jan-Michel Heger, Cologne, DE
Edith Julia, Pierre-Bénite, FR
Mouhamad Khouja, Kiel, DE
Anna Laube, Berlin, DE
Amira Marouf, Paris, FR
Bernard Douglas Maybury, Birmingham, GB
Patrizia Mondello, New York, NY, US
Skye Montoya, Miami, FL, US
Laura Ondrisova, Brno, CZ
Ivana Spasevska, Oslo, NO

The Organizing Committee is proud to release the content of the Late Breaking Abstracts session, taking place in Room A on Saturday, June 17 (10:15 - 11:30).

The session will be chaired by Franco Cavalli, Bellinzona, CH and Martin Dreyling, Munich, DE and will encompass the following presentations:
 

• LBA1 - Genome-wide association study of childhood Burkitt Lymphoma in East Africa identifies a novel germline susceptibility locus on chromosome 21.
  Sam M. Mbulaiteye, Rockville, MD, US
   
• LBA2 - Ibrutinib plus BR or R-CHOP in previously treated patients with Follicular or Marginal Zone Lymphoma: the Phase 3 SELENE Study.
  Loretta J. Nastoupil, Houston, TX, US
   
• LBA3 - Lisocabtagene maraleucel (liso-cel) in R/R MCL: primary analysis results from the MCL cohort of the single-arm, multicenter, seamless design TRANSCEND NHL 001 study.
  Michael L. Wang, Houston, TX, US
   
• LBA4 - TRANSCEND FL: Phase 2 study results of lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL).
  Franck Morschhauser, Lille, FR
   
• LBA5 - BrECADD is non-inferior to eBEACOPP in patients with advanced stage classical Hodgkin Lymphoma: efficacy results of the GHSG phase III HD21 trial.
  Peter Borchmann, Cologne, DE